These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32555574)

  • 1. [One-year follow-up of Italian patients with atrial fibrillation treated with edoxaban in ETNA-AF Europe].
    Ameri P; Riva L; Toma M; Di Pasquale G; De Caterina R
    G Ital Cardiol (Rome); 2020 Jul; 21(7):546-557. PubMed ID: 32555574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
    De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
    BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
    De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Reimitz PE; Kirchhof P;
    J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):97-104. PubMed ID: 30540648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study.
    Kirchhof P; Bakhai A; de Asmundis C; de Groot JR; Deharo JC; Kelly P; Lopez-de-Sa E; Monteiro P; Fronk EM; Lamparter M; Laeis P; Smolnik R; Steffel J; Waltenberger J; Weiss TW; De Caterina R;
    Int J Cardiol; 2024 Aug; 408():132118. PubMed ID: 38697397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
    Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study.
    Unverdorben M; von Heymann C; Santamaria A; Saxena M; Vanassche T; Jin J; Laeis P; Wilkins R; Chen C; Colonna P
    BMC Cardiovasc Disord; 2020 Dec; 20(1):504. PubMed ID: 33256590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study.
    de Groot JR; Weiss TW; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Waltenberger J; Steffel J; Levy P; Bakhai A; Zierhut W; Laeis P; Manu MC; Reimitz PE; De Caterina R; Kirchhof P
    Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f30-f39. PubMed ID: 32790837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study.
    Blann AD; Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
    Int J Cardiol; 2015 Dec; 201():693-8. PubMed ID: 26379097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ETNA-AF study: Italian baseline data and comparison with the European population in atrial fibrillation patients treated with edoxaban].
    Riva L; Diemberger I; Di Pasquale G; Attena E; Sangiuolo R; De Caterina R
    G Ital Cardiol (Rome); 2020 Feb; 21(2):141-151. PubMed ID: 32051638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.
    Okumura K; Akao M; Yoshida T; Kawata M; Okazaki O; Akashi S; Eshima K; Tanizawa K; Fukuzawa M; Hayashi T; Akishita M; Lip GYH; Yamashita T;
    N Engl J Med; 2020 Oct; 383(18):1735-1745. PubMed ID: 32865374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Minguet J; Sims HM; Smith KH; Bramlage P
    Expert Rev Clin Pharmacol; 2017 Jan; 10(1):5-15. PubMed ID: 27817212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Uninterrupted Periprocedural Edoxaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation　- The Prospective KYU-RABLE Study.
    Takahashi N; Mukai Y; Kimura T; Yamaguchi K; Matsumoto T; Origasa H; Okumura K;
    Circ J; 2019 Sep; 83(10):2017-2024. PubMed ID: 31511436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
    Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Periprocedural edoxaban interruption is associated with low bleeding and thromboembolic risk: the Italian data of the EMIT-AF/VTE study].
    Fazio G; Squizzato A; Mazzetti M; Mannarini A; Fischetti A; Colonna P
    G Ital Cardiol (Rome); 2021 Jan; 22(1):70-79. PubMed ID: 33470246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.
    Carnicelli AP; De Caterina R; Halperin JL; Renda G; Ruff CT; Trevisan M; Nordio F; Mercuri MF; Antman E; Giugliano RP;
    Circulation; 2017 Mar; 135(13):1273-1275. PubMed ID: 28209729
    [No Abstract]   [Full Text] [Related]  

  • 17. Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Score-Matched Study.
    Rago A; Papa AA; Attena E; Parisi V; Golino P; Nigro G; Russo V
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1003-1007. PubMed ID: 32946035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial.
    Nicolau AM; Corbalan R; Nicolau JC; Ruff CT; Zierhut W; Kerschnitzki M; Duris T; Juul-Möller S; Voitk J; Trevisan M; Nordio F; Antman EM; Giugliano RP
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):167-175. PubMed ID: 31687762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data.
    Monteiro P
    Rev Port Cardiol (Engl Ed); 2020 Nov; 39(11):651-662. PubMed ID: 33190965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial.
    Akashi S; Oguri M; Ikeno E; Manita M; Taura J; Watanabe S; Hayashi T; Akao M; Okumura K; Akishita M; Yamashita T
    JAMA Netw Open; 2022 Aug; 5(8):e2228500. PubMed ID: 35997978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.